4 月 29 日,百济神州公布了泽布替尼涉及诉讼的最近进展。美国专利商标局(USPTO)裁定,Pharmacyclics(艾伯维子公司)在‘803 专利授权后复审(PGR)程序中受到公司质疑的‘803 专利的全部权利无效,即‘803 专利过于宽泛和无效。Pharmacyclics 可对 USPTO 的最终书面决定提起上诉。来源:百济神州公告2023 年 6 月,Pharmacyclics 在美国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.